Provided by Tiger Trade Technology Pte. Ltd.

Adlai Nortye Biopharma Co. Ltd.

15.06
+1.329.61%
Post-market: 14.97-0.0900-0.60%19:54 EDT
Volume:149.69K
Turnover:2.18M
Market Cap:969.83M
PE:-26.66
High:15.11
Open:13.70
Low:13.50
Close:13.74
52wk High:17.25
52wk Low:0.8786
Shares:64.40M
Float Shares:45.14M
Volume Ratio:1.14
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5649
EPS(LYR):-1.1111
ROE:-20.23%
ROA:-8.70%
PB:4.51
PE(LYR):-13.55

Loading ...

Major Insider Move Shakes Up Adlai Nortye’s Market Narrative

TIPRANKS
·
1 hour ago

Adlai Nortye Calls September Extraordinary Meeting to Authorize Major Share Issuance and Board Changes

TIPRANKS
·
Yesterday

Prince Harry, Elton John and other celebrities hit with initial $13 million bill after losing case against UK tabloid

CNN Business
·
Aug 21

Analysts’ Opinions Are Mixed on These Healthcare Stocks: US Physical Therapy (USPH) and Adlai Nortye Ltd. Sponsored ADR (ANL)

TIPRANKS
·
Aug 15

Earnings Flash (ANL) Adlai Nortye Posts H1 Revenue $13.1M

MT Newswires Live
·
Aug 14

Adlai Nortye FY26 H1 Net Loss Narrows 70.9% to Us$5.3 Million; Revenue Turns to Us$13.1 Million

Reuters
·
Aug 14

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

THOMSON REUTERS
·
Aug 14

Adlai Nortye Director Lars Erik Birgerson Files Initial Beneficial Ownership Statement

Reuters
·
Aug 04

Adlai Nortye Receives Ethics Approval to Begin Phase 1 Trial of Cancer Drug AN4035

MT Newswires Live
·
Aug 03

Adlai Nortye - in Process of Ind Submissions for An4035 to U.S. FDA and China Nmpa

THOMSON REUTERS
·
Aug 03

Adlai Nortye Announces Clinical Trial Notification Submission and Hrec Approval for the Phase I Clinical Trial of Pan-Ras(on) Inhibitor ADC An4035 in Australia

THOMSON REUTERS
·
Aug 03

Adlai Nortye Initiated With Buy on Differentiated RAS-Targeting Pipeline, ADC Strategy and Solid Cash Runway

TIPRANKS
·
Jul 27

Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald

TIPRANKS
·
Jul 20

Adlai Nortye Doses First US Patient in Weekly Arm of Phase 1 AN9025 Trial

MT Newswires Live
·
Jul 16

Adlai Nortye doses first patient in AN9025 trial

TIPRANKS
·
Jul 16

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-ras(on) Inhibitor An9025

THOMSON REUTERS
·
Jul 16

Adlai Nortye Director Roger Sawhney Files Initial Beneficial Ownership Statement

Reuters
·
Jul 15

Adlai Nortye Adds MD Anderson’s David Hong, Msk’s Piro Lito to Scientific Advisory Board

Reuters
·
Jul 13

Press Release: Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

Dow Jones
·
Jul 13

Prince Harry loses privacy case against UK tabloid publisher

CNN Business
·
Jul 07